Pfizer (PFE) named an interim head of finance on Thursday as it announced the departure of Chief Financial Officer Dave Denton.
Cecile Guegan, the US drugmaker's senior vice president of finance for the global biopharmaceutical business, will serve as interim CFO, beginning Aug. 16, Pfizer said in a statement. Guegan has been with Pfizer for more than 20 years.
Denton will leave the company on Aug. 15, having accepted an opportunity in the consumer goods industry, Pfizer said.
Separately, the company affirmed its fiscal 2026 guidance, according to a regulatory filing.
It continues to expect full-year adjusted per-share earnings of $2.80 to $3 and revenue between $59.5 billion to $62.5 billion. Analysts in a FactSet poll are looking for non-GAAP EPS of $2.96 on sales of $61.74 billion.
Pfizer previously reported 2025 adjusted EPS of $3.22 and revenue of $62.58 billion.
Last month, Pfizer posted higher-than-expected first-quarter results as robust demand across its key brands offset weakening sales of its COVID-19 products.
Shares of Pfizer were down 2.7% in late afternoon trade on Thursday. The stock is up 1.3% so far this year.
Price: $25.29, Change: $-0.64, Percent Change: -2.45%



